[Complement components, whole complement activity, and circulating immune complexes in neoplastic diseases].
Serum levels of complement components(cc), whole complement activity (CH 50), and circulating immune complexes (IC) were measured in 41 patients with neoplastic diseases. The level of cc was higher than in healthy controls; the levels of C1q, C1INA, C4, C3c, C3ACT, C5, and C9 were statistically higher. In patients with lung cancer, the levels of cc were correlated with the clinical stage as well as the performance status. Both the IC serum level and the incidence of high serum IC levels in lung cancer were higher in stage III and IV than in stage I and II. Serum CH 50 was higher than in healthy controls, but not correlated with the clinical stage.
D000368:Aged; D000936:Antigen-Antibody Complex / Q000032:analysis*; D003166:Complement Activating Enzymes / Q000032:analysis; D003167:Complement Activation; D003174:Complement C1 Inactivator Proteins / Q000032:analysis; D015922:Complement C1q; D003176:Complement C3 / Q000032:analysis; D050577:Complement C3-C5 Convertases / Q000032:analysis; D015932:Complement C3c; D003181:Complement C4 / Q000032:analysis; D003182:Complement C5 / Q000032:analysis; D003186:Complement C9 / Q000032:analysis; D003165:Complement System Proteins / Q000032:analysis*; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology*
D000936:Antigen-Antibody Complex; D003174:Complement C1 Inactivator Proteins; D003176:Complement C3; D003181:Complement C4; D003182:Complement C5; D003186:Complement C9; D015922:Complement C1q; D015932:Complement C3c; D003165:Complement System Proteins; D003166:Complement Activating Enzymes; D050577:Complement C3-C5 Convertases